Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results
Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumi...
Saved in:
Main Author: | Oey A. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/88166 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Modeling household dynamics on Respiratory Syncytial Virus (RSV)
by: Wiriya Mahikul, et al.
Published: (2020) -
Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication
by: Nattamon Niyomdecha, et al.
Published: (2022) -
Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting
by: Timothy Kinyanjui, et al.
Published: (2020) -
Mathematical Modeling: Global Stability Analysis of Super Spreading Transmission of Respiratory Syncytial Virus (RSV) Disease
by: Sungchasit R.
Published: (2023) -
Motavizumab, a neutralizing anti-respiratory syncytial virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model
by: Mejías, A, et al.
Published: (2020)